AXIM Biotechnologies Submits 510(k) to FDA for Next-Generation, Rapid Point-of-Care Tear ...

AXIM Biotechnologies has submitted a 510(k) premarket notification to the FDA for its next-generation rapid lateral-flow tear lactoferrin test to diagnose aqueous deficient dry eye disease, aiming for a CLIA waiver to enable broader point-of-care use.

This Wire brief sits within Fusion42's coverage of Diagnostics.